Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.57 |
| ▸ | MMP9 | P14780 | 16/20 | 0.57 |
| ▸ | MMP1 | P03956 | 8/20 | 0.50 |
| ▸ | MMP3 | P08254 | 8/20 | 0.50 |
| ▸ | MMP13 | P45452 | 8/20 | 0.50 |
| ▸ | MMP7 | P09237 | 7/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.50 |
| ▸ | MMP12 | P39900 | 4/20 | 0.50 |
| ▸ | MMP14 | P50281 | 4/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839753 | 0.78 | MMP2 (0.58) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL8839750 | 0.78 | MMP2 (0.58) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6415418 | 0.77 | MMP2 (0.63) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6413229 | 0.77 | MMP2 (0.57) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6418837 | 0.76 | MMP2 (0.66) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6415170 | 0.75 | MMP2 (0.69) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6419176 | 0.74 | MMP2 (0.60) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL8839572 | 0.74 | MMP2 (0.57) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL8839281 | 0.74 | MMP2 (0.57) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL8839291 | 0.74 | MMP2 (0.57) | MMP2MMP9MMP1MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.